How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
Essential thrombocythaemia (ET) is an acquired myeloproliferative disorder. The phenotypic and biological heterogeneity of ET can make management of individual cases problematic, especially in the era of changing ideas on the molecular pathogenesis of this disease process. This case discussion will explore the evidence base and rationale that guides treatment of a 46-year-old individual with ET presenting with an ischaemic episode.
McLornan
Dp
D
Department of Haematology, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Northern Ireland, BT7 1NN, UK. donalmclornan@aol.com
McMullin
Mf
M
D001241:Aspirin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D007511:Ischemia / Q000209:etiology*; D053614:Janus Kinase 2 / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D012306:Risk; D013920:Thrombocythemia, Essential / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D014034:Toes / Q000098:blood supply*
D016898:Interferon-alpha; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D001241:Aspirin; D006918:Hydroxyurea